Results 181 to 190 of about 453,940 (280)

The Emerging Parkinson's Disease Oxylipin‐Ome

Advanced Science, EarlyView.
ABSTRACT Parkinson Disease (PD) is increasingly considered a proteinopathy and lipidopathy. This proteinopathy+lipidopathy paradigm has been further refined to a fatty acid (FA)‐opathy, centering dysregulated FA metabolism as fundamental in PD lipid dysfunction.
Julia C. Kelliher, Saranna Fanning
wiley   +1 more source

Dissecting Alzheimer's disease heritability across populations. [PDF]

Alzheimers Dement
Liu S, Bush WS, Kunkle BW, Byrd GS, Reitz C, Tosto G, Rajabli F, Caban-Holt AM, Cuccaro M, Starks T, Adams LD, Feliciano BE, Akinyemi R, Vance JM, Pericak-Vance M, Haines JL, Crawford DC, Williams SM.   +17 more
europepmc   +1 more source

NIR‐II Imaging‐Guided Photothermal Activation of a TRPV4‐Targeted Nanoplatform Delivering Cycloastragenol to Promote Microglia Reprogramming and α‐Synuclein Clearance in Parkinson's Disease

Advanced Science, EarlyView.
ABSTRACT Current therapies for Parkinson's disease (PD) fail to concurrently address α‐synuclein (α‐syn) aggregation and microglia‐mediated neuroinflammation. Herein, we engineer a near‐infrared‐II (NIR‐II) phototheranostic nanoplatform, CAG/FD1080@MM‐aTRPV4, for synergistic regulation of microglial function and real‐time monitoring of PD pathology. We
Hsuan Lo, Linjuan Feng, Shiying Li, Lik Hang Hugo Tse, Xuehan Wang, Xingyang Zhao, Shaoheng Ma, Xin Li, Yanjuan Gu, Wing‐Tak Wong   +9 more
wiley   +1 more source

Loss of REST associated with Alzheimer's disease pathology is ameliorated by NAD. [PDF]

Brain
Lagartos-Donate MJ, Escobar-Doncel B, Zhang SQ, Pan JP, Villaseca González N, Anisimov A, Montaldo NP, Jensen V, Mao L, Li B, Banzon-Pereira N, Shi L, Cao SQ, Caponio D, Wang P, Nair RR, Luo OJ, Chen G, Nevado-Holgado AJ, Buckley N, Nilsen HL, Fang EF.   +21 more
europepmc   +1 more source

Brain and Liver Dual‐Targeting Oridonin Nanoparticles to Enhance Aβ Clearance for Alzheimer's Disease Therapy

Advanced Science, EarlyView.
We developed a nanoparticle named OAF, which simultaneously targeted to both the brain and liver via the transferrin receptor 1 (TfR1) receptor, promoting lipoprotein receptor‐related protein 1 (LRP1) expression to enhance amyloid‐beta (Aβ) clearance. In AD mice model, OAF significantly reduced Aβ deposition and cognitive impairment, while a mitigating
Wenshuai Gong, Wenting Hui, Sai Qiao, Qifeng Ji, Miao Liu, Bangle Zhang, Daozhou Liu, Yumei Wu, Siyuan Zhou   +8 more
wiley   +1 more source

The neuromodulatory fragility hypothesis of Alzheimer's disease pathogenesis. [PDF]

Alzheimers Dement
Wearn A, Onuska KM, Schmitz TW, Turner GR, Spreng RN.   +4 more
europepmc   +1 more source

Alzheimer's Disease Risk Factor APOE4 Exerts Dimorphic Effects on Female Bone

Advanced Science, EarlyView.
In aging bone, osteocytes accumulate neurodegenerative risk factor Apolipoprotein E (APOE). A humanized version of the Alzheimer's disease risk allele APOE4 altered the mouse bone transcriptome and proteome, with effects in female bone surpassing the brain, including bone fragility due to suppressed osteocytic maintenance of bone quality, identifying ...
Charles A. Schurman, Gurcharan Kaur, Serra Kaya, Joanna Bons, Carlos Galicia Aguirre, Qi Liu, Christina D. King, Kenneth A. Wilson, Harrison L. Baker, Mikayla Hady, Nadja Maldonado Luna, Gregor Bieri, Saul A. Villeda, Lisa M. Ellerby, Birgit Schilling, Tamara Alliston   +15 more
wiley   +1 more source